Literature DB >> 36187512

Ex Situ In Vivo Technique of Spleen-Preserving Splenic Hilar Lymph Node Dissection in Operable Proximal Gastric Adenocarcinoma.

V C Kalyanasundarabharathi1, C Kolandasamy1, R Prabhakaran1, M J Chandrabose Ambedkar1, Arjun Balram1, S Rajendran1, Naganath Babu Obla Lakshmanamoorthy1.   

Abstract

D2 gastrectomy is the globally accepted standard surgical procedure for operable gastric cancer, and lymph node (LN) dissection is considered as the critical part of radical surgery and closely related to the prognosis. The splenic hilar LN (SHLN) or level 10 are to be removed during standard D2 total gastrectomy. In situ and ex situ spleen-preserving lymphadenectomies have been the most common dissection approaches for SHLNs. No study exists which compares the outcomes of these techniques in Indian population. This study is aimed to analyse the operative outcomes of ex situ in vivo technique of spleen-preserving splenic hilar lymph node dissection in patients who underwent D2 total gastrectomy for operable proximal gastric cancer in comparison with in situ in vivo technique of splenic hilar lymph node dissection. We reviewed prospectively collected data from 17 patients with operable proximal gastric cancer between September 2016 and April 2019 who underwent D2 total gastrectomy with splenic hilar lymph node dissection and studied the preoperative demographic factors, operative and postoperative outcomes comparing the different operative techniques. Patients with oesophago-gastric junction involvement, direct splenic or other adjacent organ invasion requiring multivisceral resection and gastric stump carcinoma were excluded. Overall, 17 patients underwent D2 total gastrectomy for operable gastric cancer. Mean age of presentation was 54.7 years including 13 males and 4 females. Five patients had middle third and 12 patients had upper third cancer. All patients had splenic hilar nodal clearance as follows: in situ - 14 and ex situ - 3 patients. R0 resection was achieved in all patients. Lymph node harvest tends to be higher with lower operative time and blood loss in patients with ex situ technique compared to in situ technique with similar morbidity. Ex situ in vivo technique of spleen-preserving splenic hilar lymph node dissection can be considered as both safe and feasible procedure for operable proximal gastric cancer patients in experienced centres to achieve better lymph node yield with no significant increase in morbidity. © Indian Association of Surgical Oncology 2022.

Entities:  

Keywords:  D2 total gastrectomy; Ex situ in vivo technique; Operable proximal gastric adenocarcinoma; Spleen preserving node dissection; Splenic hilar lymphnode

Year:  2022        PMID: 36187512      PMCID: PMC9515299          DOI: 10.1007/s13193-021-01487-2

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  12 in total

1.  Frequency of lymph node metastasis to the splenic hilus and effect of splenectomy in proximal gastric cancer.

Authors:  Shinsuke Sasada; Motoki Ninomiya; Masahiko Nishizaki; Masao Harano; Yasutomo Ojima; Hiroyoshi Matsukawa; Hideki Aoki; Shigehiro Shiozaki; Satoshi Ohno; Norohisa Takakura
Journal:  Anticancer Res       Date:  2009-08       Impact factor: 2.480

2.  Lymph node metastasis at the splenic hilum in proximal gastric cancer.

Authors:  Masahide Ikeguchi; Nobuaki Kaibara
Journal:  Am Surg       Date:  2004-07       Impact factor: 0.688

3.  Gastric cancer in India: epidemiology and standard of treatment.

Authors:  Chandramohan Servarayan Murugesan; Kanagavel Manickavasagam; Apsara Chandramohan; Abishai Jebaraj; Abdul Rehman Abdul Jameel; Mayank Shikar Jain; Jayanthi Venkataraman
Journal:  Updates Surg       Date:  2018-04-02

4.  Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma.

Authors:  Takeshi Sano; Mitsuru Sasako; Junki Mizusawa; Seiichiro Yamamoto; Hitoshi Katai; Takaki Yoshikawa; Atsushi Nashimoto; Seiji Ito; Masahide Kaji; Hiroshi Imamura; Norimasa Fukushima; Kazumasa Fujitani
Journal:  Ann Surg       Date:  2017-02       Impact factor: 12.969

5.  Comparison of different methods of splenic hilar lymph node dissection for advanced upper- and/or middle-third gastric cancer.

Authors:  Xin Ji; Tao Fu; Zhao-De Bu; Ji Zhang; Xiao-Jiang Wu; Xiang-Long Zong; Zi-Yu Jia; Biao Fan; Yi-Nan Zhang; Jia-Fu Ji
Journal:  BMC Cancer       Date:  2016-10-03       Impact factor: 4.430

6.  Efficacy of prophylactic splenectomy for proximal advanced gastric cancer invading greater curvature.

Authors:  Yu Ohkura; Shusuke Haruta; Junichi Shindoh; Tsuyoshi Tanaka; Masaki Ueno; Harushi Udagawa
Journal:  World J Surg Oncol       Date:  2017-05-25       Impact factor: 2.754

7.  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Authors:  Daniel Dindo; Nicolas Demartines; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

8.  Japanese gastric cancer treatment guidelines 2014 (ver. 4).

Authors: 
Journal:  Gastric Cancer       Date:  2016-06-24       Impact factor: 7.370

9.  Japanese gastric cancer treatment guidelines 2018 (5th edition).

Authors: 
Journal:  Gastric Cancer       Date:  2020-02-14       Impact factor: 7.370

10.  Comparisons Between Different Procedures of No. 10 Lymphadenectomy for Gastric Cancer Patients With Total Gastrectomy.

Authors:  Kun Yang; Zheng-Hao Lu; Wei-Han Zhang; Kai Liu; Xin-Zu Chen; Xiao-Long Chen; Dong-Jiao Guo; Zong-Guang Zhou; Jian-Kun Hu
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.